Therakind enters exclusive distribution partnership with BioJam Holding Group
Launch of Jylamvo in Portugal
14 March 2020 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, has entered into an exclusive distribution agreement with BioJam Holding Group (“BioJam”) for Therakind’s lead product, Jylamvo.
Under this agreement, BioJam secures exclusive rights to market, commercialise and sell Jylamvo in Portugal and Spain, where today the partnership has also announced its successful Launch in Portugal. Jylamvo is already on sale in UK, Middle East, Poland, Romania and Greece.
Jylamvo is a novel methotrexate 2mg/ml Oral Solution which is licensed for use in adults and children over three years old for the treatment of rheumatological disorders (adult and juvenile) and adult psoriasis and psoriatic arthritis, and for the maintenance treatment of acute lymphoblastic leukaemia (ALL). Jylamvo has a marketing authorization which allows it to be sold throughout the European Economic Area and is the first oral liquid formulation of methotrexate to be authorised in Europe for the treatment of polyarthritic juvenile idiopathic arthritis (JIA).
Jylamvo as an oral liquid is easier for patients with swallowing difficulties to take than tablets and its use eliminates dosing inaccuracies and unnecessary exposure to the cytotoxic methotrexate powder which may occur if tablets are crushed. As a licensed oral liquid, Jylamvo has proven stability and no inappropriate excipients which may be the case with unlicensed oral liquids. Jylamvo also has a palatable orange taste which masks methotrexate’s bitter taste. It also addresses compliance issues which may occur with methotrexate injections due to patients’ fear of needles and intolerance of injection site pain and reaction.
Dr Susan Conroy, CEO of Therakind, said:
“We believe in designing medicines tailored to the patient. We are delighted to partner with BioJam and announce the potential availability of Jylamvo, our flagship product, in Spain and Portugal. It is an easy to take, pleasant tasting liquid medicine for children and adults which will simplify their treatment regime. This partnership builds on strategy to partner with specialists in countries who have the expertise and network to broaden access to Jylamvo.”
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
